Brian E. Kadera

Brian E. Kadera, MD

Surgical Oncology
Primary Location
Surgery - Santa Monica
1304 15th Street
Suite 102
Santa Monica, California 90404
Phone
Fax
310-825-6213

About

Dr. Kadera's clinical practice includes general surgical oncology, with an emphasis in soft tissue sarcoma and gastrointestinal malignancies (stomach, small bowel, appendiceal, colon, etc.), including minimally invasive and robotically-assisted surgery.

He trained in general surgery at UCLA, where he spent two extra years doing full-time cancer research. He studied two important reasons why pancreatic cancer is so resistant to chemotherapy, both because of signaling from fibroblasts that support the cancer cell and the cancer cell's ability to stimulate its own growth receptors.

Dr. Kadera then spent two years in surgical oncology fellowship at one of the world's premier clinical and research hospitals, Memorial Sloan Kettering Cancer Center in New York. There, he operated on a high volume of complex surgical cases for sarcoma, gastric, liver, pancreas, and colorectal malignancies, and participated in cutting edge clinical trials.

He is fortunate enough to be married to Samantha Kadera, MD, and is the proud "Papa" to Sienna and Broderick "Brody."

Education

Medical Board Certifications

Complex General Surgical Oncology, American Board of Surgery, 2019
Surgery, American Board of Surgery, 2016

Fellowship

Memorial Sloan-Kettering Cancer Center, 2018

Residency

UCLA School of Medicine, 2016

Internship

UCLA School of Medicine, 2010

Degree

Duke University Medical Center, MD, 2009

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center

Research

Interests

Dr. Kadera is working to improve outcomes in soft tissue sarcoma and GI malignancies by defining molecular pathways that predict local and distant recurrence. He has a particular interest in targeted therapy and the development of neoadjuvant clinical trials.

He is a member of the UCLA Jonsson Comprehensive Cancer Center in the Signal Transduction and Therapeutics program.

Publications

Recent Publications

  1. Kadera BE, Lum K, DeMaria EJ, Yurcisin B, Gaddor M, Portenier DD. Remission of type 2 diabetes after Roux-en-Y gastric bypass is associated with greater weight loss. SOARD. 2009;5(3):305-309. PMID: 19460674.<//li>
  2. Kadera BE, DeMaria EJ, Yurcisin B, Gaddor M, Portenier DD. Evidence for a metabolic mechanism in the improvement of type 2 diabetes after sleeve gastrectomy in a rodent model. SOARD. 2013;9(3):447-52. PMID: 23462596.
  3. Rochefort M, Ankeny J, Kadera BE, Donald G, Isacoff W, Wainberg Z, Hines OJ, Donahue T, Reber H, Tomlison J. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Ann Surg Oncol. 2013;20(13):4322-9. PMID: 23943022.
  4. Kadera BE, Li L, Toste P, Wu N, Adams C, Dawson DD, Donahue TR. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS ONE. 2013;8(8):e71978. PMID: 23991015.
  5. Toste PA, Kadera BE, Tatishchev SF, Dawson DW, Clerkin BM, Muthusamy R, Watson R, Tomlison JS, Hines OJ, Reber HA, Donahue TR. Non-functional pancreatic neuroendocrine tumors < 2cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival. J Gastrointest Surg.
    2013;17(12)2105-13. PMID: 24101447.
  6. Kadera BE, Sunjaya DB, Isacoff WH, Li L, Hines OJ, Tomlinson JS, Dawson DW, Rochefort, MM, Donald GW, Clerkin BM, Reber HA, Donahue TR. Locally advanced pancreatic cancer: prolonged preoperative treatment is associated with lymph node negativity and excellent overall survival. JAMA Surg. 2014;149(2):145-53. PMID: 24306217.
  7. Kadera BE, Toste PA, Wu N, Li L, Nguyen AH, Dawson DW, Donahue TR. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. Clin Cancer Res. 2015;21(1)157-65. PMID 25348515.
  8. Toste PA, Li L, Kadera BE, Nguyen AH, Tran LM, Wu N, Madnick DL, Patel SG, Dawson DW, Donahue TR. p85? is a microRNA target and affects chemosensitivity in pancreatic cancer. J Surg Res. 2015;196(2):285-93. PMID: 25846727.
  9. Toste PA, Nguyen AH, Kadera BE, Duong M, Wu N, Gawlas I, Tran LM, Bikhchandani M, Li L, Patel SG, Dawson DW, Donahue TR. Chemotherapy-induced inflammatory gene signature and pro-tumorigenic phenotype in pancreatic CAFs via stress-associated MAPK. Mol Cancer Res. 2016;14(5):437-47. PMID 26979711.
  10. Williams JL, Kadera BE, Nguyen AH, Muthusamy VR, Wainberg ZA, Hines OJ, Reber HA, Donahue TR. CA 19-9 normalization during pre-operative treatment predicts longer survival for patients with locally progressed pancreatic cancer. J Gastroinstest Surg. 2016 Jul;20(7):1331-42. PMID 27114246.

Link to complete list of PubMed publications >

Awards

  • Super Doctors® Southern California Rising Stars 2021
  • Super Doctors® Southern California Rising Stars 2020
  • UCLA Department of Surgery Research Award - 2016
  • UCLA Department of Surgery Outstanding Student Teaching Award - 2011-2013
  • California Institute of Regenerative Medicine Grant (TG2-01169) - 2011-2013
  • Gerald S. Levey Research Scholarship - 2011 - 2013
  • UCLA Division of Cardiothoracic Surgery, Resident of the Year - 2011
  • UCLA Department of Surgery Most Outstanding First Year Resident - 2010